Orion

Orion is a leading Finnish pharmaceutical company that develops, manufactures, and markets human and veterinary pharmaceuticals as well as active pharmaceutical ingredients. The company focuses on core therapy areas including oncology, neurological disorders, and respiratory diseases, with a significant emphasis on prostate cancer and Parkinson's disease. Orion's flagship product, Nubeqa (darolutamide), is a key growth driver developed in global partnership with Bayer. Additionally, Orion maintains a strong presence in the respiratory market through its Easyhaler inhaler technology and operates a robust contract manufacturing and generics business. Headquartered in Espoo, Finland, Orion is a major player in the Nordic healthcare sector and is listed on the Nasdaq Helsinki.